Healthcare / Drug Manufacturers - Specialty & GenericBSE
$2022.15
+9.75 (+0.48%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 23%
FCF escenarios
weak_data · normalized FCF $439.2M · quality 49.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
54/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$17.2B
P/E
29.9x
↑EV/EBITDA
18.1x
↑ROE
15.4%
↑Gross Margin
75.4%
↑Debt/Equity
0.54
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+7.7%
FCF CAGR
—
FCF margin
13.9%
FCF / Net income
0.83x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.33B · net income $556.4M · FCF $463.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.33B | $3.33B | $3.11B | $3.05B | $2.66B |
| Net Income | $556.4M | $556.4M | $274.9M | $188.9M | $266.3M |
| EBITDA | $1.06B | $1.06B | $690.8M | $582.5M | $660.0M |
| EPS | — | — | 33.89 | 22.20 | 31.30 |
| Gross Margin | 75.4% | 75.4% | 71.6% | 63.8% | 67.7% |
| Operating Margin | 20.4% | 20.4% | 14.2% | 13.9% | 15.6% |
| Net Margin | 16.7% | 16.7% | 8.8% | 6.2% | 10.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.54 | 0.54 | 0.68 | 0.84 | 0.98 |
| Current Ratio | 1.37 | 1.37 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $463.1M | $463.1M | $439.2M | $237.9M | $-541.7M |
| Returns | |||||
| ROE | 15.4% | 15.4% | 8.7% | 6.5% | 9.5% |
| Valuation | |||||
| P/E | 29.90 | 29.90 | 52.45 | 72.93 | 56.28 |
| EV/EBITDA | 18.10 | 18.10 | 23.88 | 27.63 | 26.67 |
| P/B | 4.78 | 4.78 | 4.59 | 4.72 | 5.36 |
| Growth & Yield | |||||
| Revenue Growth | 6.9% | 6.9% | 2.2% | 14.5% | — |
| EPS Growth | — | — | 52.6% | -29.1% | — |
| Dividend Yield | 0.3% | 0.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+11.5%
Start / end P/E
n/dx → n/dx
EPS bridge
33.89 → n/d
Residual
+11.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.